Biocon Biologics Ltd, a fully integrated ‘pure play’ biosimilars company and a subsidiary of Biocon Ltd, is pleased to partner with The International Diabetes Federation (IDF) as the first biosimilar insulin company to promote and support IDF’s core mission initiative and activities.

This important partnership with IDF coincides with the start of the centenary celebrations of the discovery of insulin and takes forward Biocon Biologics’ mission of enabling affordable access to insulins to people with diabetes worldwide.

Dr Alexander Zach, Global Head of Market Access & Policy, Biocon Biologics, said, “We are delighted to partner with the International Diabetes Federation and contribute to a stronger global voice for people living with diabetes. Given our extensive experience in providing affordable insulins globally, we believe we can contribute and support IDF in driving real policy and access actions that will transform lives and diabetes care.”

Prof Andrew Boulton, President, International Diabetes Federation (IDF), said, “It is with great pleasure that IDF welcomes Biocon Biologics as a new partner. This year, we celebrate the centenary of the development of therapeutic insulin in 1921 and next year its first successful use to treat a person with diabetes in 1922. Yet, 100 years after its discovery, this life-saving drug remains beyond the reach of many people with diabetes who need it. For IDF and our partners, the centenary of insulin will provide opportunities to raise awareness of diabetes, promote action to improve access to diabetes care and encourage greater effort to prevent diabetes and its complications.”